Decode Age Raises ₹14.48 crore in Pre Series A funding to Advance Longevity Science and Gut Microbiome Research

Decode Age, a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science, has raised ₹14.48 crore in its Pre Series A funding round led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited.  With over forty years of experience in the pharmaceutical industry, Dr Prasad has been a pioneer of innovation, scale and manufacturing excellence. 

The investment strengthens the company’s mission to make the biology of ageing measurable, understandable and actionable through science led solutions and a microbiome centred longevity ecosystem.

Decode Age has built a comprehensive longevity research platform that spans multi omics testing, biomarker discovery and precision-based interventions. At the heart of this ecosystem is one of India’s most advanced whole genome gut microbiome analysis systems, providing high resolution insights into microbial diversity and its influence on immunity, metabolism and ageing pathways. Its laboratory workflows prioritise precision and reproducibility, supporting researchers, clinicians and individuals who seek deeper biological understanding and practical tools for healthy ageing.

The company is using these insights to develop a new generation of research driven supplements and longevity solutions that are informed by ageing biology and microbiome data. The focus is on supporting healthy ageing and biological pathways that sit behind age related conditions such as cancer, dementia and other chronic diseases, in line with prevailing scientific evidence and regulatory standards. The new capital will enable Decode Age to expand biomarker discovery programmes, advance its multi omics and microbiome research pipeline and enhance scientific and analytical infrastructure. It will also support formulation research aligned with key hallmarks of ageing, including areas such as cellular energy, metabolic balance, inflammatory pathways and cognitive resilience, as well as deeper collaboration across the longevity ecosystem.

Speaking about the investment, Parth Amin, CEO and Co-founder, Decode Age, said, “This investment marks an important step forward in our mission to bring scientific precision to the way people understand their biology. The support from Dr Chigurupati strengthens our ability to advance ageing and gut microbiome research, expand our biomarker programmes and build the scientific infrastructure that drives our work. We are grateful for his belief in our vision and remain committed to translating rigorous science into insights that help individuals make informed decisions about their long-term health.”

Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited, added, “Decode Age is advancing an area of science that will redefine how we think about health, disease and ageing. Their capabilities in gut microbiome research and ageing biology are rigorous and forward-looking, offering individuals and clinicians biological insights that were previously inaccessible. This investment reflects my confidence in their scientific vision and the long-term impact they aim to create.”

Decode Age is now also building a world class scientific, clinical, and product team to take India’s longevity innovation to a global audience. The company aims to position India as a leader in microbiome science and healthy ageing research, and to create solutions that meet international standards of scientific rigour, quality and translational value. This next phase of growth will strengthen its ability to operate at global research scale while delivering accessible, evidence backed longevity solutions for consumers.  

Decode Age contributes to India’s growing longevity ecosystem through its collaboration with the Indian Institute of Science and global longevity Initiative like XPRIZE through partnership, where it supports microbiome linked data generation, analysis and longevity medicines. These partnerships reinforce the company’s commitment to advancing scientifically robust and globally aligned ageing research and to connecting academic insight with real world applications.

Since its inception in 2021, the company has established advanced metagenomics and microbiome laboratories, introduced whole genome microbiome analysis for individuals and developed precision designed formulations informed by ageing biology and microbiome science. These milestones provide a strong foundation for its next phase of research and scale as Decode Age builds an integrated longevity ecosystem that links laboratories, clinicians, partners and individuals.